Drug Profile
CCT 289346
Alternative Names: CCT289346Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Institute of Cancer Research
- Developer Institute of Cancer Research; Phenex Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Breast-cancer(Combination therapy) in United Kingdom (PO)
- 17 May 2017 Institute of Cancer Research plans a phase I trial for Breast cancer (Combination therapy) (Institute of Cancer Research website, May 2017)
- 01 Apr 2017 Preclinical trials in Breast cancer (Combination therapy) in United Kingdom (PO)